Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Contrasting ABVC BioPharma (NASDAQ:ABVC) and Edgewise Therapeutics (NASDAQ:EWTX)

Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month High – Should You Buy?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

SG Americas Securities LLC Buys 78,842 Shares of Edgewise Therapeutics, Inc. $EWTX

Edgewise Therapeutics (NASDAQ:EWTX) CMO Joanne Donovan Sells 28,662 Shares

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Why Edgewise Therapeutics Stock Topped the Market on Tuesday

The $3B Biotech With Two Shots On Goal

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Head to Head Survey: Edgewise Therapeutics (NASDAQ:EWTX) and Sarepta Therapeutics (NASDAQ:SRPT)

Why Edgewise Therapeutics Stock Crushed the Market on Monday

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Badreddin Edris Sells 115,471 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock

Campbell & CO Investment Adviser LLC Lowers Holdings in Edgewise Therapeutics, Inc. $EWTX

Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits

Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst

Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.2% – Time to Sell?

Why Edgewise Therapeutics Stock Rocked the Market Today

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 11.9% – Still a Buy?

Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX